Do [ Tissue engineered bone regeneration of periosteal cells using recombinant human bone morphogenetic protein 2 induce ]?
The constructed tissue engineering bone has emerged as another promising alternative for bone repair.
The PPARgamma agonist RG exerts antioxidant properties that significantly reduced Nrf-2-dependent CD-36 up-regulation in mice under HFHC diet. Because LST treatment was also associated with a preserved PPARgamma activity, our data suggests that these RG antioxidant effects are partially independent of its PPARgamma metabolizing properties.